Businesses
Here's a look at documents from U.S. and international businesses
Businesses
Featured Stories
Marcus & Millichap Brokers $5.32M Sale of Willowbrae Academy Property in Sun Prairie, Wisconsin
ENCINO, California, June 25 -- Marcus and Millichap issued the following news release on June 24, 2026:
* * *
Marcus & Millichap Brokers $5.32M Sale of Willowbrae Academy Property in Sun Prairie, Wisconsin
SUN PRAIRIE, Wis.- Marcus & Millichap (NYSE: MMI), a leading commercial real estate brokerage firm specializing in investment sales, financing, research and advisory services, announced today the sale of a net-leased childcare facility, occupied by Willowbrae Academy, in Sun Prairie, Wisconsin. The property sold for $5.32 million.
"By leveraging our team's deep expertise in the early education ... Show Full Article ENCINO, California, June 25 -- Marcus and Millichap issued the following news release on June 24, 2026: * * * Marcus & Millichap Brokers $5.32M Sale of Willowbrae Academy Property in Sun Prairie, Wisconsin SUN PRAIRIE, Wis.- Marcus & Millichap (NYSE: MMI), a leading commercial real estate brokerage firm specializing in investment sales, financing, research and advisory services, announced today the sale of a net-leased childcare facility, occupied by Willowbrae Academy, in Sun Prairie, Wisconsin. The property sold for $5.32 million. "By leveraging our team's deep expertise in the early educationsector, we were able to complete this transaction off-market and connect the buyer with a property that closely aligned with his investment objectives," said Dominic Sulo, senior managing director investments.
Sulo, investment specialist in Marcus & Millichap's Chicago Oak Brook office, in association with Todd Lindblom, Marcus & Millichap's Wisconsin broker of record, marketed the property on behalf of the seller, a repeat Chicago-based developer.
Sulo and Sam Malato, director investments in the firm's Chicago Oak Brook office, procured the local Wisconsin-based 1031 exchange buyer.
Situated at 1340 Merchant Square, Willowbrae Academy is a newly built, 11,790-square-foot property on 1.16 acres, secured by a triple-net lease with more than 14 years remaining. The tenant operates multiple locations across the U.S. and Canada.
* * *
About Marcus & Millichap, Inc. (NYSE: MMI)
Marcus & Millichap, Inc. is a leading brokerage firm specializing in commercial real estate investment sales, financing, research and advisory services with offices throughout the United States and Canada. As of December 31, 2025, the company had 1,808 investment sales and financing professionals in over 80 offices who provide investment brokerage and financing services to sellers and buyers of commercial real estate. The company also offers market research, consulting and advisory services to clients. Marcus & Millichap closed 8,818 transactions in 2025, with a sales volume of approximately $50.9 billion. For additional information, please visit www.MarcusMillichap.com.
* * *
Original text here: https://www.marcusmillichap.com/news-events/press/2026/06/06-24-willowbraeacademy
[Category: BizRealEstate]
* * *
Marcus & Millichap Brokers $5.32M Sale of Willowbrae Academy Property in Sun Prairie, Wisconsin
SUN PRAIRIE, Wis.- Marcus & Millichap (NYSE: MMI), a leading commercial real estate brokerage firm specializing in investment sales, financing, research and advisory services, announced today the sale of a net-leased childcare facility, occupied by Willowbrae Academy, in Sun Prairie, Wisconsin. The property sold for $5.32 million.
"By leveraging our team's deep expertise in the early education ... Show Full Article ENCINO, California, June 25 -- Marcus and Millichap issued the following news release on June 24, 2026: * * * Marcus & Millichap Brokers $5.32M Sale of Willowbrae Academy Property in Sun Prairie, Wisconsin SUN PRAIRIE, Wis.- Marcus & Millichap (NYSE: MMI), a leading commercial real estate brokerage firm specializing in investment sales, financing, research and advisory services, announced today the sale of a net-leased childcare facility, occupied by Willowbrae Academy, in Sun Prairie, Wisconsin. The property sold for $5.32 million. "By leveraging our team's deep expertise in the early educationsector, we were able to complete this transaction off-market and connect the buyer with a property that closely aligned with his investment objectives," said Dominic Sulo, senior managing director investments.
Sulo, investment specialist in Marcus & Millichap's Chicago Oak Brook office, in association with Todd Lindblom, Marcus & Millichap's Wisconsin broker of record, marketed the property on behalf of the seller, a repeat Chicago-based developer.
Sulo and Sam Malato, director investments in the firm's Chicago Oak Brook office, procured the local Wisconsin-based 1031 exchange buyer.
Situated at 1340 Merchant Square, Willowbrae Academy is a newly built, 11,790-square-foot property on 1.16 acres, secured by a triple-net lease with more than 14 years remaining. The tenant operates multiple locations across the U.S. and Canada.
* * *
About Marcus & Millichap, Inc. (NYSE: MMI)
Marcus & Millichap, Inc. is a leading brokerage firm specializing in commercial real estate investment sales, financing, research and advisory services with offices throughout the United States and Canada. As of December 31, 2025, the company had 1,808 investment sales and financing professionals in over 80 offices who provide investment brokerage and financing services to sellers and buyers of commercial real estate. The company also offers market research, consulting and advisory services to clients. Marcus & Millichap closed 8,818 transactions in 2025, with a sales volume of approximately $50.9 billion. For additional information, please visit www.MarcusMillichap.com.
* * *
Original text here: https://www.marcusmillichap.com/news-events/press/2026/06/06-24-willowbraeacademy
[Category: BizRealEstate]
How Gallup Developed Global Survey Questions About AI
WASHINGTON, June 25 (TNSres) -- Gallup, a research-based and performance-management consulting company, issued the following news:
* * *
How Gallup Developed Global Survey Questions About AI
By Charles Lau and Alvin Nugroho
Despite artificial intelligence's growing influence worldwide, no standardized global data exist yet to help us understand how people are thinking about it. To address this data gap, Gallup is currently measuring AI awareness, use and attitudes in more than 140 countries through its 2026 World Poll.
Collecting comparable data about AI across 140+ countries is inherently ... Show Full Article WASHINGTON, June 25 (TNSres) -- Gallup, a research-based and performance-management consulting company, issued the following news: * * * How Gallup Developed Global Survey Questions About AI By Charles Lau and Alvin Nugroho Despite artificial intelligence's growing influence worldwide, no standardized global data exist yet to help us understand how people are thinking about it. To address this data gap, Gallup is currently measuring AI awareness, use and attitudes in more than 140 countries through its 2026 World Poll. Collecting comparable data about AI across 140+ countries is inherentlydifficult. AI awareness and use vary substantially by country, so what might be easy to understand and relevant in one country could be confusing to people in another.
Uneven adoption adds another layer of complexity to global research on AI. We expect to find that large segments of people in many countries have heard of AI but haven't ever used it, meaning their knowledge will be limited. Yet it is important to represent these "aware nonusers" in a meaningful way.
AI is a broad concept, encompassing different types of technologies. And because we intend to compare these data over time, we need a question set that will remain relevant as AI use expands and as the technology evolves.
Building such a survey that works across diverse populations requires careful testing. Before finalizing the questions, Gallup conducted cognitive interviews in Colombia, India, South Africa and the United Kingdom in November and December 2025. The 48 participants included AI users and nonusers. Local interviewers explored how participants interpreted the draft questions, how they retrieved information, formed judgments and arrived at answers.
The interviews yielded important insights that informed the final survey questions and shed light on how people conceptualize AI. This blog summarizes several key lessons from the cognitive interviewing study.
People Think AI = Generative AI
Gallup started the interviews with an unaided question about what AI means to people. Participants generally referenced chatbots, often excluding other AI-enabled technologies such as search tools, smart home devices or predictive business systems. In South Africa, some participants referred to AI generically as "ChatGPT," even when thinking about other AI tools.
AI Needs to Be Defined Through Use Cases and Tools
To provide a shared understanding of AI for survey participants, Gallup experimented with different ways to define AI. Across countries, an abstract, conceptual definition ("AI enables computers or other devices to do things that usually require human thinking") proved more confusing than helpful for participants.
Our final definition instead incorporates the most common use cases (writing text; creating images, audio and video; answering questions), and names specific AI tools, with the examples used tailored to each country's context.
Asking About Awareness Matters
Given that the Gallup World Poll is conducted in over 140 countries, including many where AI adoption is still nascent, it is important to ask an AI awareness question. This will let us track how AI awareness spreads over time and allows us to skip the questions about AI use and attitudes for nonaware respondents.
"Daily" Users Are Not All the Same
When we probed AI users about their frequency of using AI for work and personal reasons, we found that "daily" was too broad to serve as the most-frequent category, because it grouped people who use AI once per day with people who use AI multiple times per day. These groups strongly differed in their patterns of use and sentiments toward AI. Our final question added these distinctions to the scale to better identify high-frequency users.
Capturing Emotional Complexity
Gallup tested a seemingly straightforward question about respondents' feelings on the future of AI, asking, "When you think about the future, does AI make you feel more hopeful or more worried?" The responses were anything but simple. This question resonated strongly with participants, generating more substantive and thoughtful responses than other general opinion questions about AI -- views that a binary choice between "hopeful" and "worried" couldn't capture.
Participants pushed back against the "either/or" framing of the question in several ways:
* Ambivalence: Many participants expressed both positive and negative feelings about AI: One participant from India said she was "70% hopeful and 30% worried." A South Africa participant said, "It can very easily replace me in my industries. But I do feel like it could also make the world better for everybody if we allow it to."
* Multifaceted emotions: A simple "good/bad" dichotomy didn't capture the diverse emotions raised by participants. For example, a single participant in South Africa expressed a host of emotions, including pride (referring to ChatGPT as his 15th employee in his company), unease (concern about job displacement in South Africa) and even fear ("This thing is gonna kill us ... because if it knows how we think, it knows our weaknesses. It knows all this personal information").
* Self versus others: Some participants wanted to differentiate AI's effects on themselves versus others. For example, a U.K. participant mentioned, "I am not so worried for myself, but one aspect where I am more worried generally is jobs, especially those early in their careers."
* Future versus current status: Current sentiments about AI did not always align with expectations about where the technology is headed. For example, one Indian participant said, "In the future, it [AI] might become better, but for now, it feels like AI can also be dangerous and even ruin lives."
Our final questionnaire asked respondents separate yes/no questions about whether they felt various ways about AI (e.g., happy, sad, worried).
Even Nonusers Have Opinions About AI
A key design question was whether "aware nonusers" (i.e., people who know about AI but do not use it personally) can provide informed responses to questions about AI. While these participants were understandably less knowledgeable than AI users, our probing revealed that many nonusers had reasoned, thoughtful answers. For example, one nonuser from India explained that AI tools improve as they receive more training data.
Our testing suggests that it is possible to ask attitudinal questions about AI among nonusers. While these initial impressions are encouraging, Gallup will be closely monitoring comprehension among this group during the 2026 World Poll data collection process before drawing firm conclusions.
What Comes Next
The 2026 World Poll will be the first real test of these items on a global scale. As data collection scales to 140+ countries spanning differing levels of AI adoption, we will pay particular attention to whether our AI definition produces comparable responses across diverse settings, how emotions toward AI may differ between countries, and whether nonusers can still provide meaningful attitudinal responses.
* * *
Jenna Steinberg contributed to this article.
Stay up to date with the latest insights by following @Gallup on X and on Instagram.
* * *
Original text here: https://news.gallup.com/opinion/methodology/711806/gallup-developed-global-survey-questions.aspx
[Category: BizConsulting]
* * *
How Gallup Developed Global Survey Questions About AI
By Charles Lau and Alvin Nugroho
Despite artificial intelligence's growing influence worldwide, no standardized global data exist yet to help us understand how people are thinking about it. To address this data gap, Gallup is currently measuring AI awareness, use and attitudes in more than 140 countries through its 2026 World Poll.
Collecting comparable data about AI across 140+ countries is inherently ... Show Full Article WASHINGTON, June 25 (TNSres) -- Gallup, a research-based and performance-management consulting company, issued the following news: * * * How Gallup Developed Global Survey Questions About AI By Charles Lau and Alvin Nugroho Despite artificial intelligence's growing influence worldwide, no standardized global data exist yet to help us understand how people are thinking about it. To address this data gap, Gallup is currently measuring AI awareness, use and attitudes in more than 140 countries through its 2026 World Poll. Collecting comparable data about AI across 140+ countries is inherentlydifficult. AI awareness and use vary substantially by country, so what might be easy to understand and relevant in one country could be confusing to people in another.
Uneven adoption adds another layer of complexity to global research on AI. We expect to find that large segments of people in many countries have heard of AI but haven't ever used it, meaning their knowledge will be limited. Yet it is important to represent these "aware nonusers" in a meaningful way.
AI is a broad concept, encompassing different types of technologies. And because we intend to compare these data over time, we need a question set that will remain relevant as AI use expands and as the technology evolves.
Building such a survey that works across diverse populations requires careful testing. Before finalizing the questions, Gallup conducted cognitive interviews in Colombia, India, South Africa and the United Kingdom in November and December 2025. The 48 participants included AI users and nonusers. Local interviewers explored how participants interpreted the draft questions, how they retrieved information, formed judgments and arrived at answers.
The interviews yielded important insights that informed the final survey questions and shed light on how people conceptualize AI. This blog summarizes several key lessons from the cognitive interviewing study.
People Think AI = Generative AI
Gallup started the interviews with an unaided question about what AI means to people. Participants generally referenced chatbots, often excluding other AI-enabled technologies such as search tools, smart home devices or predictive business systems. In South Africa, some participants referred to AI generically as "ChatGPT," even when thinking about other AI tools.
AI Needs to Be Defined Through Use Cases and Tools
To provide a shared understanding of AI for survey participants, Gallup experimented with different ways to define AI. Across countries, an abstract, conceptual definition ("AI enables computers or other devices to do things that usually require human thinking") proved more confusing than helpful for participants.
Our final definition instead incorporates the most common use cases (writing text; creating images, audio and video; answering questions), and names specific AI tools, with the examples used tailored to each country's context.
Asking About Awareness Matters
Given that the Gallup World Poll is conducted in over 140 countries, including many where AI adoption is still nascent, it is important to ask an AI awareness question. This will let us track how AI awareness spreads over time and allows us to skip the questions about AI use and attitudes for nonaware respondents.
"Daily" Users Are Not All the Same
When we probed AI users about their frequency of using AI for work and personal reasons, we found that "daily" was too broad to serve as the most-frequent category, because it grouped people who use AI once per day with people who use AI multiple times per day. These groups strongly differed in their patterns of use and sentiments toward AI. Our final question added these distinctions to the scale to better identify high-frequency users.
Capturing Emotional Complexity
Gallup tested a seemingly straightforward question about respondents' feelings on the future of AI, asking, "When you think about the future, does AI make you feel more hopeful or more worried?" The responses were anything but simple. This question resonated strongly with participants, generating more substantive and thoughtful responses than other general opinion questions about AI -- views that a binary choice between "hopeful" and "worried" couldn't capture.
Participants pushed back against the "either/or" framing of the question in several ways:
* Ambivalence: Many participants expressed both positive and negative feelings about AI: One participant from India said she was "70% hopeful and 30% worried." A South Africa participant said, "It can very easily replace me in my industries. But I do feel like it could also make the world better for everybody if we allow it to."
* Multifaceted emotions: A simple "good/bad" dichotomy didn't capture the diverse emotions raised by participants. For example, a single participant in South Africa expressed a host of emotions, including pride (referring to ChatGPT as his 15th employee in his company), unease (concern about job displacement in South Africa) and even fear ("This thing is gonna kill us ... because if it knows how we think, it knows our weaknesses. It knows all this personal information").
* Self versus others: Some participants wanted to differentiate AI's effects on themselves versus others. For example, a U.K. participant mentioned, "I am not so worried for myself, but one aspect where I am more worried generally is jobs, especially those early in their careers."
* Future versus current status: Current sentiments about AI did not always align with expectations about where the technology is headed. For example, one Indian participant said, "In the future, it [AI] might become better, but for now, it feels like AI can also be dangerous and even ruin lives."
Our final questionnaire asked respondents separate yes/no questions about whether they felt various ways about AI (e.g., happy, sad, worried).
Even Nonusers Have Opinions About AI
A key design question was whether "aware nonusers" (i.e., people who know about AI but do not use it personally) can provide informed responses to questions about AI. While these participants were understandably less knowledgeable than AI users, our probing revealed that many nonusers had reasoned, thoughtful answers. For example, one nonuser from India explained that AI tools improve as they receive more training data.
Our testing suggests that it is possible to ask attitudinal questions about AI among nonusers. While these initial impressions are encouraging, Gallup will be closely monitoring comprehension among this group during the 2026 World Poll data collection process before drawing firm conclusions.
What Comes Next
The 2026 World Poll will be the first real test of these items on a global scale. As data collection scales to 140+ countries spanning differing levels of AI adoption, we will pay particular attention to whether our AI definition produces comparable responses across diverse settings, how emotions toward AI may differ between countries, and whether nonusers can still provide meaningful attitudinal responses.
* * *
Jenna Steinberg contributed to this article.
Stay up to date with the latest insights by following @Gallup on X and on Instagram.
* * *
Original text here: https://news.gallup.com/opinion/methodology/711806/gallup-developed-global-survey-questions.aspx
[Category: BizConsulting]
GSK Announces Commencement of Tender Offer to Acquire Nuvalent Inc.
LONDON, England, June 25 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on June 24, 2026:
* * *
GSK announces commencement of tender offer to acquire Nuvalent, Inc.
GSK plc (LSE/NYSE: GSK) today announced that Harmony Row Acquisition Co. ("Purchaser"), a direct wholly-owned subsidiary of GlaxoSmithKline LLC ("GSK LLC"), which is an indirect wholly-owned subsidiary of GSK, has commenced a tender offer to purchase all of the issued and outstanding shares of Class A Common Stock, par value $0.0001 per share (the "Class A Shares"), and Class B Common ... Show Full Article LONDON, England, June 25 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on June 24, 2026: * * * GSK announces commencement of tender offer to acquire Nuvalent, Inc. GSK plc (LSE/NYSE: GSK) today announced that Harmony Row Acquisition Co. ("Purchaser"), a direct wholly-owned subsidiary of GlaxoSmithKline LLC ("GSK LLC"), which is an indirect wholly-owned subsidiary of GSK, has commenced a tender offer to purchase all of the issued and outstanding shares of Class A Common Stock, par value $0.0001 per share (the "Class A Shares"), and Class B CommonStock, par value $0.0001 per share (the "Class B Shares" and, together with the Class A Shares, the "Shares") of Nuvalent, Inc. ("Nuvalent") (NASDAQ: NUVL), for $124.00 per Share, net to the seller in cash, without interest, subject to any applicable withholding taxes, and upon the terms and subject to the conditions set forth in the Offer to Purchase, dated June 24, 2026, and the accompanying Letter of Transmittal (together, and with other related materials, as they may be amended or supplemented from time to time, the "Offer").
The Offer is being made pursuant to an Agreement and Plan of Merger, dated as of June 9, 2026, by and among Nuvalent, GSK LLC, Purchaser and solely for purposes of Section 9.14 therein, GSK. As soon as practicable following consummation of the Offer and subject to the satisfaction or waiver of certain conditions, Purchaser will merge with and into Nuvalent (the "Merger") and the separate existence of Purchaser will cease and Nuvalent will continue as the surviving corporation and as a direct wholly-owned subsidiary of GSK LLC. The Merger will be governed by Section 251(h) of the General Corporation Law of the State of Delaware, as amended (the "DGCL"), which does not require a vote or action by written consent of Nuvalent's stockholders.
Nuvalent's Board of Directors (the "Nuvalent Board") has published a Solicitation/Recommendation Statement on Schedule 14D-9 (the "Schedule 14D-9") filed with the Securities and Exchange Commission (the "SEC"), which includes, among other things, the recommendation of the Nuvalent Board that Nuvalent's stockholders accept the Offer and tender their Shares to Purchaser pursuant to the Offer.
The Offer and withdrawal rights will expire at one minute following 11:59 p.m., Eastern Time, on July 14, 2026, unless the Offer is extended or earlier terminated (such date, or any subsequent date to which the expiration of the Offer is extended, the "Expiration Date"). Any extension, delay, termination or amendment of the Offer will be followed as promptly as practicable by a public announcement thereof, and such announcement, in the case of an extension, will be made no later than 9:00 a.m., Eastern Time, on the next business day after the previously scheduled Expiration Date. Purchaser is not providing for guaranteed delivery procedures.
Purchaser's obligation to pay for Shares validly tendered (and not validly withdrawn) pursuant to the Offer is subject to certain conditions, including, among others, (a) the Minimum Tender Condition (as defined below); and (b) the expiration or termination of the waiting period (and any extension thereof) under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The "Minimum Tender Condition" means that there shall have been validly tendered in the Offer and "received" by the "depositary" (as such terms are defined in Section 251(h) of the DGCL), and not validly withdrawn prior to the Expiration Date that number of Class A Shares that, together with the number of Class A Shares, if any, then owned beneficially by GSK LLC and Purchaser (together with their wholly-owned subsidiaries), represents at least a majority of the Class A Shares outstanding as of the consummation of the Offer. The Offer is not subject to a financing condition.
The documentation relating to the Offer (including the Offer to Purchase, the Letter of Transmittal and Schedule 14D-9) can be accessed at the following link: www.readourmaterials.com/gsk2026/. The Offer to Purchase, the related Letter of Transmittal and the Schedule 14D-9 (which contains the recommendation of the Nuvalent Board and the reasons therefor) contain important information. Nuvalent's stockholders should carefully read all documents in their entirety before any decision is made with respect to the Offer.
Questions or requests for assistance may be directed to Innisfree M&A Incorporated (the "Information Agent") at the address and telephone numbers set forth below. Requests for copies of the Offer to Purchase, the related Letter of Transmittal and other tender offer materials may be directed to the Information Agent or to brokers, dealers, commercial banks or trust companies. Such copies will be furnished promptly at Purchaser's expense.
INNISFREE M&A INCORPORATED
500 Fifth Avenue, 21st Floor
New York, NY 10110
Shareholders May Call Toll Free: (877) 750-5838 (from the U.S. and Canada), or +1 (412) 232-3651 (from other countries)
Banks and Brokers May Call Collect: (212) 750-5833
* * *
Additional information
This press announcement is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell securities of Nuvalent, nor is it a substitute for any tender offer materials that GSK, GSK LLC, Purchaser or Nuvalent have filed with the SEC. GSK, GSK LLC and Purchaser have filed a Tender Offer Statement on Schedule TO with the SEC with respect to the Offer, and Nuvalent has filed a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the Offer. The Offer is being made solely pursuant to the Offer to Purchase, and the exhibits filed with respect thereto (including the Letter of Transmittal), which contain the full terms and conditions of the Offer. The Offer is not being made to (nor will tenders be accepted from or on behalf of) holders of Shares in any jurisdiction in which the making of the Offer or the acceptance thereof would not be in compliance with the securities, "blue sky" or other laws of such jurisdiction. In those jurisdictions where applicable laws or regulations require the Offer to be made by a licensed broker or dealer, the Offer shall be deemed to be made on behalf of Purchaser (as defined below) by one or more registered brokers or dealers licensed under the laws of such jurisdiction to be designated by Purchaser. NUVALENT STOCKHOLDERS ARE URGED TO READ THE TENDER OFFER MATERIALS (INCLUDING THE OFFER TO PURCHASE, THE RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER DOCUMENTS RELATING TO THE OFFER) AND THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 BECAUSE THEY CONTAIN IMPORTANT INFORMATION THAT SHOULD BE READ CAREFULLY BEFORE ANY DECISION IS MADE WITH RESPECT TO THE OFFER. The Offer to Purchase, the related Letter of Transmittal and certain other documents relating to the Offer, as well as the Solicitation/Recommendation Statement on Schedule 14D-9, have been sent to all record holders of Shares whose names appear on Nuvalent's stockholder list. The Tender Offer Statement on Schedule TO, the Solicitation/Recommendation Statement on Schedule 14D-9, and other related documents are available for free at the SEC's website at www.sec.gov. Additional copies may be obtained for free by contacting the Information Agent or to brokers, dealers, commercial banks or trust companies.
In addition to the Offer to Purchase, the related Letter of Transmittal and certain other documents relating to the Offer, as well as the Solicitation/Recommendation Statement on Schedule 14D-9, Nuvalent and GSK file or furnish, as applicable, annual, quarterly and current reports and other information with the SEC. Nuvalent's and GSK's filings with the SEC are available to the public from commercial document-retrieval services and at the SEC's website at www.sec.gov
* * *
About Nuvalent
Nuvalent (NASDAQ: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, Nuvalent develops innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs.
* * *
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
* * *
Cautionary statement regarding forward-looking statements
GSK plc cautions investors that any forward-looking statements or projections made by GSK plc, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the "Risk Factors" section in GSK plc's Annual Report on Form 20-F for the year ended December 31, 2025, and GSK's Q1 Results for 2026. This communication includes forward-looking statements related to Nuvalent, and the acquisition of Nuvalent by GSK plc that are subject to risks, uncertainties and other factors. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including all statements regarding the intent, belief or current expectation of Nuvalent and members of its senior management team and can typically be identified by words such as "believe," "expect," "estimate," "predict," "target," "potential," "likely," "continue," "ongoing," "could," "should," "intend," "may," "might," "plan," "seek," "anticipate," "project" and similar expressions, as well as variations or negatives of these words. Forward-looking statements include, without limitation, statements regarding the merger, similar transactions, prospective performance, future plans, events, expectations, performance, objectives and opportunities and the outlook for Nuvalent's business; the ability of Nuvalent to successfully commercialize its key products, including neladalkib and zidesamtinib; the anticipated timing of clinical data and regulatory filings or approvals relating to products; the possibility of favorable or unfavorable results from clinical trials; the anticipated benefits of the acquisition; filings and approvals relating to the transaction; the expected timing of the completion of the transaction; the parties' ability to complete the transaction; and the accuracy of any assumptions underlying any of the foregoing. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those currently anticipated due to a number of risks and uncertainties. Risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include: uncertainties as to the timing of the tender offer and completion of the merger; the possibility that various closing conditions for the transaction may not be satisfied or waived, including that Nuvalent stockholders may not tender into the offer a majority of the shares of Class A common stock outstanding at the time of the expiration of the offer or that required regulatory approvals may not be obtained or are obtained subject to conditions that are not anticipated; the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement; the failure to realize anticipated benefits of the proposed acquisition when expected or at all; potential adverse reactions or changes to business relationships resulting from the proposed acquisition, including the effect of the announcement, pendency or consummation of the acquisition on the ability of Nuvalent to retain and hire key personnel or maintain key vendor, supplier or partner relationships; risks that the proposed acquisition disrupts the current plans and operations of Nuvalent; transaction costs; risks associated with potential litigation or regulatory actions related to the transaction; and other risks and uncertainties described from time to time in documents filed with the SEC by Nuvalent, including current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K, as well as the Schedule 14D-9 filed by Nuvalent, or in GSK plc's Annual Report on Form 20-F for the year ended December 31, 2025 filed with the SEC by GSK plc, as well as the Schedule TO filed by GSK plc. All forward-looking statements are based on information currently available to GSK plc and Nuvalent, and neither GSK plc nor Nuvalent assumes any obligation to update any forward-looking statements.
GSK uses a number of adjusted measures, including Core results, to report the performance of its business, which are non-IFRS measures. These measures are defined and reconciliations to the nearest IFRS measure are available in GSK's Q1 2026 Results and GSK's Annual Report on Form 20-F for FY 2025.
GSK provides earnings guidance to the investor community on the basis of Core results. This is in line with peer companies and expectations of the investor community, supporting easier comparison of the Group's performance with its peers. GSK is not able to give guidance for Total results as it cannot reliably forecast certain material elements of the Total results, particularly the future fair value movements on contingent consideration and put options that can and have given rise to significant adjustments driven by external factors such as currency and other movements in capital markets.
All expectations, guidance and outlooks regarding future performance should be read together with the section "Guidance and outlooks, assumptions and cautionary statements" on pages 44 and 45 of GSK's Q1 2026 Results and the statements on page 328 of GSK's Annual Report for FY 2025.
* * *
Original text here: https://www.gsk.com/en-gb/media/press-releases/gsk-announces-commencement-of-tender-offer-to-acquire-nuvalent-inc/
[Category: BizPharmaceuticals]
* * *
GSK announces commencement of tender offer to acquire Nuvalent, Inc.
GSK plc (LSE/NYSE: GSK) today announced that Harmony Row Acquisition Co. ("Purchaser"), a direct wholly-owned subsidiary of GlaxoSmithKline LLC ("GSK LLC"), which is an indirect wholly-owned subsidiary of GSK, has commenced a tender offer to purchase all of the issued and outstanding shares of Class A Common Stock, par value $0.0001 per share (the "Class A Shares"), and Class B Common ... Show Full Article LONDON, England, June 25 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on June 24, 2026: * * * GSK announces commencement of tender offer to acquire Nuvalent, Inc. GSK plc (LSE/NYSE: GSK) today announced that Harmony Row Acquisition Co. ("Purchaser"), a direct wholly-owned subsidiary of GlaxoSmithKline LLC ("GSK LLC"), which is an indirect wholly-owned subsidiary of GSK, has commenced a tender offer to purchase all of the issued and outstanding shares of Class A Common Stock, par value $0.0001 per share (the "Class A Shares"), and Class B CommonStock, par value $0.0001 per share (the "Class B Shares" and, together with the Class A Shares, the "Shares") of Nuvalent, Inc. ("Nuvalent") (NASDAQ: NUVL), for $124.00 per Share, net to the seller in cash, without interest, subject to any applicable withholding taxes, and upon the terms and subject to the conditions set forth in the Offer to Purchase, dated June 24, 2026, and the accompanying Letter of Transmittal (together, and with other related materials, as they may be amended or supplemented from time to time, the "Offer").
The Offer is being made pursuant to an Agreement and Plan of Merger, dated as of June 9, 2026, by and among Nuvalent, GSK LLC, Purchaser and solely for purposes of Section 9.14 therein, GSK. As soon as practicable following consummation of the Offer and subject to the satisfaction or waiver of certain conditions, Purchaser will merge with and into Nuvalent (the "Merger") and the separate existence of Purchaser will cease and Nuvalent will continue as the surviving corporation and as a direct wholly-owned subsidiary of GSK LLC. The Merger will be governed by Section 251(h) of the General Corporation Law of the State of Delaware, as amended (the "DGCL"), which does not require a vote or action by written consent of Nuvalent's stockholders.
Nuvalent's Board of Directors (the "Nuvalent Board") has published a Solicitation/Recommendation Statement on Schedule 14D-9 (the "Schedule 14D-9") filed with the Securities and Exchange Commission (the "SEC"), which includes, among other things, the recommendation of the Nuvalent Board that Nuvalent's stockholders accept the Offer and tender their Shares to Purchaser pursuant to the Offer.
The Offer and withdrawal rights will expire at one minute following 11:59 p.m., Eastern Time, on July 14, 2026, unless the Offer is extended or earlier terminated (such date, or any subsequent date to which the expiration of the Offer is extended, the "Expiration Date"). Any extension, delay, termination or amendment of the Offer will be followed as promptly as practicable by a public announcement thereof, and such announcement, in the case of an extension, will be made no later than 9:00 a.m., Eastern Time, on the next business day after the previously scheduled Expiration Date. Purchaser is not providing for guaranteed delivery procedures.
Purchaser's obligation to pay for Shares validly tendered (and not validly withdrawn) pursuant to the Offer is subject to certain conditions, including, among others, (a) the Minimum Tender Condition (as defined below); and (b) the expiration or termination of the waiting period (and any extension thereof) under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The "Minimum Tender Condition" means that there shall have been validly tendered in the Offer and "received" by the "depositary" (as such terms are defined in Section 251(h) of the DGCL), and not validly withdrawn prior to the Expiration Date that number of Class A Shares that, together with the number of Class A Shares, if any, then owned beneficially by GSK LLC and Purchaser (together with their wholly-owned subsidiaries), represents at least a majority of the Class A Shares outstanding as of the consummation of the Offer. The Offer is not subject to a financing condition.
The documentation relating to the Offer (including the Offer to Purchase, the Letter of Transmittal and Schedule 14D-9) can be accessed at the following link: www.readourmaterials.com/gsk2026/. The Offer to Purchase, the related Letter of Transmittal and the Schedule 14D-9 (which contains the recommendation of the Nuvalent Board and the reasons therefor) contain important information. Nuvalent's stockholders should carefully read all documents in their entirety before any decision is made with respect to the Offer.
Questions or requests for assistance may be directed to Innisfree M&A Incorporated (the "Information Agent") at the address and telephone numbers set forth below. Requests for copies of the Offer to Purchase, the related Letter of Transmittal and other tender offer materials may be directed to the Information Agent or to brokers, dealers, commercial banks or trust companies. Such copies will be furnished promptly at Purchaser's expense.
INNISFREE M&A INCORPORATED
500 Fifth Avenue, 21st Floor
New York, NY 10110
Shareholders May Call Toll Free: (877) 750-5838 (from the U.S. and Canada), or +1 (412) 232-3651 (from other countries)
Banks and Brokers May Call Collect: (212) 750-5833
* * *
Additional information
This press announcement is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell securities of Nuvalent, nor is it a substitute for any tender offer materials that GSK, GSK LLC, Purchaser or Nuvalent have filed with the SEC. GSK, GSK LLC and Purchaser have filed a Tender Offer Statement on Schedule TO with the SEC with respect to the Offer, and Nuvalent has filed a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the Offer. The Offer is being made solely pursuant to the Offer to Purchase, and the exhibits filed with respect thereto (including the Letter of Transmittal), which contain the full terms and conditions of the Offer. The Offer is not being made to (nor will tenders be accepted from or on behalf of) holders of Shares in any jurisdiction in which the making of the Offer or the acceptance thereof would not be in compliance with the securities, "blue sky" or other laws of such jurisdiction. In those jurisdictions where applicable laws or regulations require the Offer to be made by a licensed broker or dealer, the Offer shall be deemed to be made on behalf of Purchaser (as defined below) by one or more registered brokers or dealers licensed under the laws of such jurisdiction to be designated by Purchaser. NUVALENT STOCKHOLDERS ARE URGED TO READ THE TENDER OFFER MATERIALS (INCLUDING THE OFFER TO PURCHASE, THE RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER DOCUMENTS RELATING TO THE OFFER) AND THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 BECAUSE THEY CONTAIN IMPORTANT INFORMATION THAT SHOULD BE READ CAREFULLY BEFORE ANY DECISION IS MADE WITH RESPECT TO THE OFFER. The Offer to Purchase, the related Letter of Transmittal and certain other documents relating to the Offer, as well as the Solicitation/Recommendation Statement on Schedule 14D-9, have been sent to all record holders of Shares whose names appear on Nuvalent's stockholder list. The Tender Offer Statement on Schedule TO, the Solicitation/Recommendation Statement on Schedule 14D-9, and other related documents are available for free at the SEC's website at www.sec.gov. Additional copies may be obtained for free by contacting the Information Agent or to brokers, dealers, commercial banks or trust companies.
In addition to the Offer to Purchase, the related Letter of Transmittal and certain other documents relating to the Offer, as well as the Solicitation/Recommendation Statement on Schedule 14D-9, Nuvalent and GSK file or furnish, as applicable, annual, quarterly and current reports and other information with the SEC. Nuvalent's and GSK's filings with the SEC are available to the public from commercial document-retrieval services and at the SEC's website at www.sec.gov
* * *
About Nuvalent
Nuvalent (NASDAQ: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, Nuvalent develops innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs.
* * *
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
* * *
Cautionary statement regarding forward-looking statements
GSK plc cautions investors that any forward-looking statements or projections made by GSK plc, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the "Risk Factors" section in GSK plc's Annual Report on Form 20-F for the year ended December 31, 2025, and GSK's Q1 Results for 2026. This communication includes forward-looking statements related to Nuvalent, and the acquisition of Nuvalent by GSK plc that are subject to risks, uncertainties and other factors. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including all statements regarding the intent, belief or current expectation of Nuvalent and members of its senior management team and can typically be identified by words such as "believe," "expect," "estimate," "predict," "target," "potential," "likely," "continue," "ongoing," "could," "should," "intend," "may," "might," "plan," "seek," "anticipate," "project" and similar expressions, as well as variations or negatives of these words. Forward-looking statements include, without limitation, statements regarding the merger, similar transactions, prospective performance, future plans, events, expectations, performance, objectives and opportunities and the outlook for Nuvalent's business; the ability of Nuvalent to successfully commercialize its key products, including neladalkib and zidesamtinib; the anticipated timing of clinical data and regulatory filings or approvals relating to products; the possibility of favorable or unfavorable results from clinical trials; the anticipated benefits of the acquisition; filings and approvals relating to the transaction; the expected timing of the completion of the transaction; the parties' ability to complete the transaction; and the accuracy of any assumptions underlying any of the foregoing. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those currently anticipated due to a number of risks and uncertainties. Risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include: uncertainties as to the timing of the tender offer and completion of the merger; the possibility that various closing conditions for the transaction may not be satisfied or waived, including that Nuvalent stockholders may not tender into the offer a majority of the shares of Class A common stock outstanding at the time of the expiration of the offer or that required regulatory approvals may not be obtained or are obtained subject to conditions that are not anticipated; the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement; the failure to realize anticipated benefits of the proposed acquisition when expected or at all; potential adverse reactions or changes to business relationships resulting from the proposed acquisition, including the effect of the announcement, pendency or consummation of the acquisition on the ability of Nuvalent to retain and hire key personnel or maintain key vendor, supplier or partner relationships; risks that the proposed acquisition disrupts the current plans and operations of Nuvalent; transaction costs; risks associated with potential litigation or regulatory actions related to the transaction; and other risks and uncertainties described from time to time in documents filed with the SEC by Nuvalent, including current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K, as well as the Schedule 14D-9 filed by Nuvalent, or in GSK plc's Annual Report on Form 20-F for the year ended December 31, 2025 filed with the SEC by GSK plc, as well as the Schedule TO filed by GSK plc. All forward-looking statements are based on information currently available to GSK plc and Nuvalent, and neither GSK plc nor Nuvalent assumes any obligation to update any forward-looking statements.
GSK uses a number of adjusted measures, including Core results, to report the performance of its business, which are non-IFRS measures. These measures are defined and reconciliations to the nearest IFRS measure are available in GSK's Q1 2026 Results and GSK's Annual Report on Form 20-F for FY 2025.
GSK provides earnings guidance to the investor community on the basis of Core results. This is in line with peer companies and expectations of the investor community, supporting easier comparison of the Group's performance with its peers. GSK is not able to give guidance for Total results as it cannot reliably forecast certain material elements of the Total results, particularly the future fair value movements on contingent consideration and put options that can and have given rise to significant adjustments driven by external factors such as currency and other movements in capital markets.
All expectations, guidance and outlooks regarding future performance should be read together with the section "Guidance and outlooks, assumptions and cautionary statements" on pages 44 and 45 of GSK's Q1 2026 Results and the statements on page 328 of GSK's Annual Report for FY 2025.
* * *
Original text here: https://www.gsk.com/en-gb/media/press-releases/gsk-announces-commencement-of-tender-offer-to-acquire-nuvalent-inc/
[Category: BizPharmaceuticals]
Fisher Phillips Issues Insight: Private Club's Guide to Workplace Investigations Involving Member Conduct - Your 5-Step Action Plan
ATLANTA, Georgia, June 25 -- Fisher Phillips, a law firm, issued the following insight on June 24, 2026:
* * *
A Private Club's Guide to Workplace Investigations Involving Member Conduct: Your 5-Step Action Plan
Private clubs face a difficult task when workplace complaints arise. You'll need to respond promptly and credibly while also navigating member relationships and legal exposure. The stakes are even higher when an employee complaint involves a member, because the club may need to balance employment concerns with member discipline procedures and club culture. We recently covered how to ... Show Full Article ATLANTA, Georgia, June 25 -- Fisher Phillips, a law firm, issued the following insight on June 24, 2026: * * * A Private Club's Guide to Workplace Investigations Involving Member Conduct: Your 5-Step Action Plan Private clubs face a difficult task when workplace complaints arise. You'll need to respond promptly and credibly while also navigating member relationships and legal exposure. The stakes are even higher when an employee complaint involves a member, because the club may need to balance employment concerns with member discipline procedures and club culture. We recently covered how toprevent member harassment and manage your club's risks in our Insight here. Now we'll explain how to conduct an effective workplace investigation that is practical, defensible, and sensitive to the membership environment. While every complaint requires a tailored response, these five steps provide a roadmap so you're ready to act.
1. Identifying the Best Investigator
When it comes to employee complaints, clubs often default to having human resources handle the issue. That may be appropriate for many concerns between employees, provided your HR staff has the training, experience, and independence needed to conduct a fair investigation. But the analysis can significantly change when the complaint involves alleged member misconduct. In these situations, you should consider:
* Reviewing your governing documents, including bylaws, codes of conduct, membership agreements, disciplinary procedures, and any complaint-handling protocols. Those documents may identify who has authority to investigate, recommend discipline, or communicate with the member. Keep independence and credibility at the forefront of those decisions. Depending on the facts, the right investigator might be a board committee, a designated club leader, or an outside investigator or counsel.
* What role standing committees could play. Many clubs have grievance, ethics, disciplinary, house, or membership committees that address member conduct. Those committees can play an important role when an employee complaint involves a member, but you should be careful to distinguish between member-discipline procedures and the club's separate obligation as an employer to respond to employee complaints. Confirm whether the committee has investigative authority, disciplinary authority, or only recommendation authority before deciding how it will interact with the investigation.
* Privilege and discoverability risks, before the investigation begins. An investigation handled internally by HR, management, the board, or another club representative generally won't carry the same confidentiality protections as an investigation directed by legal counsel. If the complaint presents significant litigation, publicity, or member-relations risk, consider involving outside counsel early so they can assess whether the investigation should be conducted under attorney-client privilege.
2. Consider Whether Interim Measures Are Needed
Launching an investigation is just the beginning, and doesn't eliminate the potential for ongoing misconduct, continued interaction between the parties, or retaliation. Always consider whether interim measures are needed while the investigation proceeds.
Be cautious about measures that burden the complaining employee. For example, moving the employee to a back-of-house role may reduce contact with the member, but it also may affect tips, hours, advancement opportunities, or other working conditions. Unless the employee voluntarily agrees to the change and the club can preserve comparable employment terms, the measure may create additional retaliation risk.
When the accused is an employee or supervisor, you may consider administrative leave, schedule changes, temporary reassignment, or modified reporting lines. Complaints involving members require additional care. A club may consider asking a member to avoid certain areas of the club, refrain from contacting the complainant, or pause club visits while the investigation is pending. But member-facing measures may raise governance, contractual, and practical issues, particularly if the club's documents do not provide a clear path.
It's also critical that these interim steps aren't framed as a determination of wrongdoing. Interim measures are not disciplinary actions and should not be viewed as a finding that the allegations are substantiated.
3. Limit the Circle of People Who Know the Details
Information can move quickly in private clubs. Employees, managers, officers, and board, committee, and general members may all hear versions of a complaint before the club has had time to assess the facts.
Establish a tight communication protocol at the start of the investigation. As a general rule, details should be limited to the investigator, key decisionmakers, necessary witnesses, and legal counsel where involved. Identify one point person for communications with the complainant, the accused, and any member or board representatives who need updates.
This approach helps protect the integrity of the investigation, reduces the risk of inconsistent messaging, and limits the chance that gossip or premature conclusions will create additional retaliation or reputational concerns.
4. Develop an Investigation Plan
A strong investigation is not improvised. Before conducting interviews, the investigator should define the scope of the complaint, identify likely witnesses, preserve relevant evidence, and map the interview sequence. Decisions to save footage or interview individuals for the investigation should be made early.
For clubs, potential evidence may include:
* schedules
* access records
* reservation records
* incident reports
* emails and text messages
* member communications
* point-of-sale records
* security footage from relevant areas
After talking with the complainant and witnesses who may have direct knowledge, the investigator typically interviews the accused after gathering enough information to present the allegations fairly and allow a meaningful response. The right order will depend on the facts, but you should be able to explain why you took this chosen sequence.
5. Document the Process with Litigation and Member Scrutiny in Mind
Documentation often determines whether a club can later show that it took a complaint seriously and responded appropriately. The investigator should document major steps taken in the investigation, including:
* the intake of the complaint
* the witness list
* interview dates
* evidence reviewed
* interim measures
* findings
* corrective action
* follow-up steps designed to prevent retaliation
The investigation file should include witness statements or interview summaries and an investigation report or closing summary. Witness statements should accurately reflect what each witness reported. The final summary should explain the investigation process, identify the information reviewed, state the factual findings, and describe any corrective or preventive action taken.
Investigators should avoid unnecessary editorial comments, speculation, or legal conclusions, especially where the materials may later become discoverable or subject to member scrutiny.
Conclusion
If you have questions, contact the authors of this Insight, your Fisher Phillips attorney, or any member of the firm's Non-Profit and Tax-Exempt Organizations team. We will continue to monitor developments affecting non-profits and tax-exempt organizations, so make sure you are subscribed to Fisher Phillips' Insight System to receive the latest updates.
* * *
Related People
Erin Gibson Allen
Partner
412.822.6635
eallen@fisherphillips.com
* * *
Daniel Barrett
Associate
404.582.8441
dbarrett@fisherphillips.com
* * *
Melissa A. Dials
Partner
440.740.2108
mdials@fisherphillips.com
* * *
Original text here: https://www.fisherphillips.com/en/insights/insights/private-clubs-guide-to-workplace-investigations-involving-member-conduct
[Category: BizLaw/Legal]
* * *
A Private Club's Guide to Workplace Investigations Involving Member Conduct: Your 5-Step Action Plan
Private clubs face a difficult task when workplace complaints arise. You'll need to respond promptly and credibly while also navigating member relationships and legal exposure. The stakes are even higher when an employee complaint involves a member, because the club may need to balance employment concerns with member discipline procedures and club culture. We recently covered how to ... Show Full Article ATLANTA, Georgia, June 25 -- Fisher Phillips, a law firm, issued the following insight on June 24, 2026: * * * A Private Club's Guide to Workplace Investigations Involving Member Conduct: Your 5-Step Action Plan Private clubs face a difficult task when workplace complaints arise. You'll need to respond promptly and credibly while also navigating member relationships and legal exposure. The stakes are even higher when an employee complaint involves a member, because the club may need to balance employment concerns with member discipline procedures and club culture. We recently covered how toprevent member harassment and manage your club's risks in our Insight here. Now we'll explain how to conduct an effective workplace investigation that is practical, defensible, and sensitive to the membership environment. While every complaint requires a tailored response, these five steps provide a roadmap so you're ready to act.
1. Identifying the Best Investigator
When it comes to employee complaints, clubs often default to having human resources handle the issue. That may be appropriate for many concerns between employees, provided your HR staff has the training, experience, and independence needed to conduct a fair investigation. But the analysis can significantly change when the complaint involves alleged member misconduct. In these situations, you should consider:
* Reviewing your governing documents, including bylaws, codes of conduct, membership agreements, disciplinary procedures, and any complaint-handling protocols. Those documents may identify who has authority to investigate, recommend discipline, or communicate with the member. Keep independence and credibility at the forefront of those decisions. Depending on the facts, the right investigator might be a board committee, a designated club leader, or an outside investigator or counsel.
* What role standing committees could play. Many clubs have grievance, ethics, disciplinary, house, or membership committees that address member conduct. Those committees can play an important role when an employee complaint involves a member, but you should be careful to distinguish between member-discipline procedures and the club's separate obligation as an employer to respond to employee complaints. Confirm whether the committee has investigative authority, disciplinary authority, or only recommendation authority before deciding how it will interact with the investigation.
* Privilege and discoverability risks, before the investigation begins. An investigation handled internally by HR, management, the board, or another club representative generally won't carry the same confidentiality protections as an investigation directed by legal counsel. If the complaint presents significant litigation, publicity, or member-relations risk, consider involving outside counsel early so they can assess whether the investigation should be conducted under attorney-client privilege.
2. Consider Whether Interim Measures Are Needed
Launching an investigation is just the beginning, and doesn't eliminate the potential for ongoing misconduct, continued interaction between the parties, or retaliation. Always consider whether interim measures are needed while the investigation proceeds.
Be cautious about measures that burden the complaining employee. For example, moving the employee to a back-of-house role may reduce contact with the member, but it also may affect tips, hours, advancement opportunities, or other working conditions. Unless the employee voluntarily agrees to the change and the club can preserve comparable employment terms, the measure may create additional retaliation risk.
When the accused is an employee or supervisor, you may consider administrative leave, schedule changes, temporary reassignment, or modified reporting lines. Complaints involving members require additional care. A club may consider asking a member to avoid certain areas of the club, refrain from contacting the complainant, or pause club visits while the investigation is pending. But member-facing measures may raise governance, contractual, and practical issues, particularly if the club's documents do not provide a clear path.
It's also critical that these interim steps aren't framed as a determination of wrongdoing. Interim measures are not disciplinary actions and should not be viewed as a finding that the allegations are substantiated.
3. Limit the Circle of People Who Know the Details
Information can move quickly in private clubs. Employees, managers, officers, and board, committee, and general members may all hear versions of a complaint before the club has had time to assess the facts.
Establish a tight communication protocol at the start of the investigation. As a general rule, details should be limited to the investigator, key decisionmakers, necessary witnesses, and legal counsel where involved. Identify one point person for communications with the complainant, the accused, and any member or board representatives who need updates.
This approach helps protect the integrity of the investigation, reduces the risk of inconsistent messaging, and limits the chance that gossip or premature conclusions will create additional retaliation or reputational concerns.
4. Develop an Investigation Plan
A strong investigation is not improvised. Before conducting interviews, the investigator should define the scope of the complaint, identify likely witnesses, preserve relevant evidence, and map the interview sequence. Decisions to save footage or interview individuals for the investigation should be made early.
For clubs, potential evidence may include:
* schedules
* access records
* reservation records
* incident reports
* emails and text messages
* member communications
* point-of-sale records
* security footage from relevant areas
After talking with the complainant and witnesses who may have direct knowledge, the investigator typically interviews the accused after gathering enough information to present the allegations fairly and allow a meaningful response. The right order will depend on the facts, but you should be able to explain why you took this chosen sequence.
5. Document the Process with Litigation and Member Scrutiny in Mind
Documentation often determines whether a club can later show that it took a complaint seriously and responded appropriately. The investigator should document major steps taken in the investigation, including:
* the intake of the complaint
* the witness list
* interview dates
* evidence reviewed
* interim measures
* findings
* corrective action
* follow-up steps designed to prevent retaliation
The investigation file should include witness statements or interview summaries and an investigation report or closing summary. Witness statements should accurately reflect what each witness reported. The final summary should explain the investigation process, identify the information reviewed, state the factual findings, and describe any corrective or preventive action taken.
Investigators should avoid unnecessary editorial comments, speculation, or legal conclusions, especially where the materials may later become discoverable or subject to member scrutiny.
Conclusion
If you have questions, contact the authors of this Insight, your Fisher Phillips attorney, or any member of the firm's Non-Profit and Tax-Exempt Organizations team. We will continue to monitor developments affecting non-profits and tax-exempt organizations, so make sure you are subscribed to Fisher Phillips' Insight System to receive the latest updates.
* * *
Related People
Erin Gibson Allen
Partner
412.822.6635
eallen@fisherphillips.com
* * *
Daniel Barrett
Associate
404.582.8441
dbarrett@fisherphillips.com
* * *
Melissa A. Dials
Partner
440.740.2108
mdials@fisherphillips.com
* * *
Original text here: https://www.fisherphillips.com/en/insights/insights/private-clubs-guide-to-workplace-investigations-involving-member-conduct
[Category: BizLaw/Legal]
Federal Court Vacates Biden-Era Davis-Bacon Provisions After Ogletree Deakins Secures Favorable Resolution
ATLANTA, Georgia, June 25 -- Ogletree Deakins, a law firm, issued the following news release on June 24, 2026:
* * *
Federal Court Vacates Biden-Era Davis-Bacon Provisions After Ogletree Deakins Secures Favorable Resolution
Ogletree Deakins, one of the largest labor and employment law firms representing management, announced today that the U.S. District Court for the Northern District of Texas entered final judgment vacating three provisions of the Biden Administration's 2023 rulemaking updating the federal Davis-Bacon Act, resolving a legal challenge the firm brought on behalf of the Associated ... Show Full Article ATLANTA, Georgia, June 25 -- Ogletree Deakins, a law firm, issued the following news release on June 24, 2026: * * * Federal Court Vacates Biden-Era Davis-Bacon Provisions After Ogletree Deakins Secures Favorable Resolution Ogletree Deakins, one of the largest labor and employment law firms representing management, announced today that the U.S. District Court for the Northern District of Texas entered final judgment vacating three provisions of the Biden Administration's 2023 rulemaking updating the federal Davis-Bacon Act, resolving a legal challenge the firm brought on behalf of the AssociatedGeneral Contractors of America (AGC) and three other entities.
Ogletree Deakins filed the lawsuit in 2023, challenging the Department of Labor's attempt to expand Davis-Bacon requirements beyond their statutory scope. The three vacated provisions would have (1) extended coverage to materials suppliers operated by contractors or subcontractors, (2) applied Davis-Bacon requirements to delivery truck drivers spending a loosely defined amount of time on jobsites, and (3) imposed the requirements retroactively on contracts that omitted the required clauses.
In 2024, Ogletree Deakins secured a nationwide preliminary injunction barring enforcement of all three provisions after the court found plaintiffs were likely to succeed in showing the rules exceeded the Department's statutory authority and were arbitrary and capricious. The Biden Administration appealed the injunction to the U.S. Court of Appeals for the Fifth Circuit.
Following the change of administration, the firm and its co-counsel entered settlement discussions with the Trump Administration's Department of Labor, reaching a resolution without further litigation. The Department ultimately declined to continue contesting the case. Today's final judgment officially vacates all three provisions on a nationwide basis.
"This result reflects what the litigation always intended -- ensuring that agency regulations are consistent with the law," said Robert Roginson, a shareholder in Ogletree Deakins' Los Angeles office and lead counsel for the plaintiffs. "Our clients sought clarity and a level playing field for contractors bidding government-funded projects, and today's judgment delivers both."
Roginson was joined by of counsel Jeffrey Londa of the firm's Houston office and shareholder Chris Murray of the firm's Indianapolis office, who assisted with the Fifth Circuit appeal. The firm served as co-counsel with Fernando Bustos of the Bustos Law Firm, P.C. and Gavoor PLLC.
* * *
About Ogletree Deakins
With more than 1,100 attorneys in 60 offices worldwide, Ogletree Deakins is one of the largest labor and employment law firms representing management. We handle all types of employment-related legal matters, including traditional labor and employment, workplace safety, employee benefits, and business immigration matters. Guided by our Client Pledge, we focus on understanding clients' business and objectives, collaborating and anticipating needs, harnessing technology and innovation, communicating effectively, and providing quality representation with exceptional value. www.ogletree.com
* * *
Original text here: https://ogletree.com/media-center/press-releases/2026-06-24/federal-court-vacates-biden-era-davis-bacon-provisions-after-ogletree-deakins-secures-favorable-resolution/?_gl=1*qw5t92*_up*MQ..*_ga*NDIyMDQ1OTYwLjE3ODIzNzIxMjE.*_ga_V4WT9JNBFT*czE3ODIzNzIxMjEkbzEkZzAkdDE3ODIzNzIxMjEkajYwJGwwJGgw
[Category: BizLaw/Legal]
* * *
Federal Court Vacates Biden-Era Davis-Bacon Provisions After Ogletree Deakins Secures Favorable Resolution
Ogletree Deakins, one of the largest labor and employment law firms representing management, announced today that the U.S. District Court for the Northern District of Texas entered final judgment vacating three provisions of the Biden Administration's 2023 rulemaking updating the federal Davis-Bacon Act, resolving a legal challenge the firm brought on behalf of the Associated ... Show Full Article ATLANTA, Georgia, June 25 -- Ogletree Deakins, a law firm, issued the following news release on June 24, 2026: * * * Federal Court Vacates Biden-Era Davis-Bacon Provisions After Ogletree Deakins Secures Favorable Resolution Ogletree Deakins, one of the largest labor and employment law firms representing management, announced today that the U.S. District Court for the Northern District of Texas entered final judgment vacating three provisions of the Biden Administration's 2023 rulemaking updating the federal Davis-Bacon Act, resolving a legal challenge the firm brought on behalf of the AssociatedGeneral Contractors of America (AGC) and three other entities.
Ogletree Deakins filed the lawsuit in 2023, challenging the Department of Labor's attempt to expand Davis-Bacon requirements beyond their statutory scope. The three vacated provisions would have (1) extended coverage to materials suppliers operated by contractors or subcontractors, (2) applied Davis-Bacon requirements to delivery truck drivers spending a loosely defined amount of time on jobsites, and (3) imposed the requirements retroactively on contracts that omitted the required clauses.
In 2024, Ogletree Deakins secured a nationwide preliminary injunction barring enforcement of all three provisions after the court found plaintiffs were likely to succeed in showing the rules exceeded the Department's statutory authority and were arbitrary and capricious. The Biden Administration appealed the injunction to the U.S. Court of Appeals for the Fifth Circuit.
Following the change of administration, the firm and its co-counsel entered settlement discussions with the Trump Administration's Department of Labor, reaching a resolution without further litigation. The Department ultimately declined to continue contesting the case. Today's final judgment officially vacates all three provisions on a nationwide basis.
"This result reflects what the litigation always intended -- ensuring that agency regulations are consistent with the law," said Robert Roginson, a shareholder in Ogletree Deakins' Los Angeles office and lead counsel for the plaintiffs. "Our clients sought clarity and a level playing field for contractors bidding government-funded projects, and today's judgment delivers both."
Roginson was joined by of counsel Jeffrey Londa of the firm's Houston office and shareholder Chris Murray of the firm's Indianapolis office, who assisted with the Fifth Circuit appeal. The firm served as co-counsel with Fernando Bustos of the Bustos Law Firm, P.C. and Gavoor PLLC.
* * *
About Ogletree Deakins
With more than 1,100 attorneys in 60 offices worldwide, Ogletree Deakins is one of the largest labor and employment law firms representing management. We handle all types of employment-related legal matters, including traditional labor and employment, workplace safety, employee benefits, and business immigration matters. Guided by our Client Pledge, we focus on understanding clients' business and objectives, collaborating and anticipating needs, harnessing technology and innovation, communicating effectively, and providing quality representation with exceptional value. www.ogletree.com
* * *
Original text here: https://ogletree.com/media-center/press-releases/2026-06-24/federal-court-vacates-biden-era-davis-bacon-provisions-after-ogletree-deakins-secures-favorable-resolution/?_gl=1*qw5t92*_up*MQ..*_ga*NDIyMDQ1OTYwLjE3ODIzNzIxMjE.*_ga_V4WT9JNBFT*czE3ODIzNzIxMjEkbzEkZzAkdDE3ODIzNzIxMjEkajYwJGwwJGgw
[Category: BizLaw/Legal]
Dentons Expands Clerkship Program Nationally to Invest in the Future of Australia's Legal Community
WASHINGTON, June 25 -- Dentons, a law firm, issued the following news:
* * *
Dentons expands Clerkship Program nationally to invest in the future of Australia's legal community
Australia--Dentons, the world's largest law firm, has announced the expansion of its Clerkship Program into a nationally coordinated initiative across its Australian offices, reinforcing its commitment to supporting and developing the next generation of legal professionals.
The program will now be rolled out across Sydney, Melbourne, Brisbane, Perth and Adelaide, providing law students across the country with access ... Show Full Article WASHINGTON, June 25 -- Dentons, a law firm, issued the following news: * * * Dentons expands Clerkship Program nationally to invest in the future of Australia's legal community Australia--Dentons, the world's largest law firm, has announced the expansion of its Clerkship Program into a nationally coordinated initiative across its Australian offices, reinforcing its commitment to supporting and developing the next generation of legal professionals. The program will now be rolled out across Sydney, Melbourne, Brisbane, Perth and Adelaide, providing law students across the country with accessto a consistent and high-quality clerkship experience.
The initiative reflects Dentons' broader purpose of "Redefining possibilities. Together, everywhere." and its role in contributing to a strong, inclusive and future-focused legal profession.
Supporting the next generation of legal talent
The national Clerkship Program is designed to give law students meaningful, practical experience early in their careers. Participants will work alongside Dentons lawyers on real client matters, while developing their legal and commercial skills through structured learning and mentoring.
"At Dentons, we don't just offer clerkships - we offer the foundation for a thriving legal career," said Australia Chair and Australasia Region CEO Amber Warren.
"Expanding our program nationally is about more than recruitment. It's about investing in the future of our legal community - providing students with access, opportunity and the support they need to succeed, regardless of where they are based."
Creating access, opportunity and experience
Through the program, clerks will:
* Gain hands-on experience working on real legal matters
* Participate in structured training and immersive learning
* Receive mentoring from experienced lawyers
* Contribute to pro bono and community initiatives
* Experience a collaborative and inclusive firm culture
The program is designed to reflect the realities of modern legal practice, offering students insight into complex, cross-border work and the opportunity to build skills that will support long-term career success.
A national platform with global reach
As part of the world's largest law firm, students participating in the program will benefit from Dentons' global platform, broad practice offering and strong community focus.
The firm's approach combines global expertise with local knowledge, enabling clerks to experience both high-quality legal work and a workplace culture that is deeply connected to the communities it serves.
Strengthening the future of the profession
By expanding the program nationally, Dentons aims to create more equitable access to career opportunities, strengthen connections with universities and student communities, and contribute to the long-term sustainability of the legal profession in Australia.
The program will run for four weeks across most offices, with an extended program of up to 10 weeks in Sydney and will align with national clerkship recruitment cycles.
Further information, including application dates and eligibility, is available via What makes Dentons different? Clerkship Program (https://students.dentons.com/opportunities-around-the-globe/australia/unlock-your-future-in-law-with-dentons-clerkship-program/).
* * *
About Dentons
Redefining possibilities. Together, everywhere. For more information visit dentons.com
* * *
Original text here: https://www.dentons.com/en/about-dentons/news-events-and-awards/news/2026/june/dentons-expands-clerkship-program-nationally-to-invest-in-the-future-of-australias-legal-community
[Category: BizLaw/Legal]
* * *
Dentons expands Clerkship Program nationally to invest in the future of Australia's legal community
Australia--Dentons, the world's largest law firm, has announced the expansion of its Clerkship Program into a nationally coordinated initiative across its Australian offices, reinforcing its commitment to supporting and developing the next generation of legal professionals.
The program will now be rolled out across Sydney, Melbourne, Brisbane, Perth and Adelaide, providing law students across the country with access ... Show Full Article WASHINGTON, June 25 -- Dentons, a law firm, issued the following news: * * * Dentons expands Clerkship Program nationally to invest in the future of Australia's legal community Australia--Dentons, the world's largest law firm, has announced the expansion of its Clerkship Program into a nationally coordinated initiative across its Australian offices, reinforcing its commitment to supporting and developing the next generation of legal professionals. The program will now be rolled out across Sydney, Melbourne, Brisbane, Perth and Adelaide, providing law students across the country with accessto a consistent and high-quality clerkship experience.
The initiative reflects Dentons' broader purpose of "Redefining possibilities. Together, everywhere." and its role in contributing to a strong, inclusive and future-focused legal profession.
Supporting the next generation of legal talent
The national Clerkship Program is designed to give law students meaningful, practical experience early in their careers. Participants will work alongside Dentons lawyers on real client matters, while developing their legal and commercial skills through structured learning and mentoring.
"At Dentons, we don't just offer clerkships - we offer the foundation for a thriving legal career," said Australia Chair and Australasia Region CEO Amber Warren.
"Expanding our program nationally is about more than recruitment. It's about investing in the future of our legal community - providing students with access, opportunity and the support they need to succeed, regardless of where they are based."
Creating access, opportunity and experience
Through the program, clerks will:
* Gain hands-on experience working on real legal matters
* Participate in structured training and immersive learning
* Receive mentoring from experienced lawyers
* Contribute to pro bono and community initiatives
* Experience a collaborative and inclusive firm culture
The program is designed to reflect the realities of modern legal practice, offering students insight into complex, cross-border work and the opportunity to build skills that will support long-term career success.
A national platform with global reach
As part of the world's largest law firm, students participating in the program will benefit from Dentons' global platform, broad practice offering and strong community focus.
The firm's approach combines global expertise with local knowledge, enabling clerks to experience both high-quality legal work and a workplace culture that is deeply connected to the communities it serves.
Strengthening the future of the profession
By expanding the program nationally, Dentons aims to create more equitable access to career opportunities, strengthen connections with universities and student communities, and contribute to the long-term sustainability of the legal profession in Australia.
The program will run for four weeks across most offices, with an extended program of up to 10 weeks in Sydney and will align with national clerkship recruitment cycles.
Further information, including application dates and eligibility, is available via What makes Dentons different? Clerkship Program (https://students.dentons.com/opportunities-around-the-globe/australia/unlock-your-future-in-law-with-dentons-clerkship-program/).
* * *
About Dentons
Redefining possibilities. Together, everywhere. For more information visit dentons.com
* * *
Original text here: https://www.dentons.com/en/about-dentons/news-events-and-awards/news/2026/june/dentons-expands-clerkship-program-nationally-to-invest-in-the-future-of-australias-legal-community
[Category: BizLaw/Legal]
AstraZeneca and YMCA of the U.S. Announce Landmark Partnership Aimed to Address Gaps in Cancer Care
WILMINGTON, Delaware, June 25 -- AstraZeneca, a biopharmaceutical company, issued the following news release on June 24, 2026:
* * *
AstraZeneca and YMCA of the USA Announce Landmark Partnership Aimed to Address Gaps in Cancer Care
Five-year, multimillion-dollar partnership kicks off with cancer screening and early detection education initiative in 75 communities
-
AstraZeneca and YMCA of the USA (Y-USA) announced today at the Aspen Ideas: Health conference, a five-year partnership focused on strengthening cancer education in the areas of screening and early detection to evidence-based programs ... Show Full Article WILMINGTON, Delaware, June 25 -- AstraZeneca, a biopharmaceutical company, issued the following news release on June 24, 2026: * * * AstraZeneca and YMCA of the USA Announce Landmark Partnership Aimed to Address Gaps in Cancer Care Five-year, multimillion-dollar partnership kicks off with cancer screening and early detection education initiative in 75 communities - AstraZeneca and YMCA of the USA (Y-USA) announced today at the Aspen Ideas: Health conference, a five-year partnership focused on strengthening cancer education in the areas of screening and early detection to evidence-based programshelping cancer survivors living with, through and beyond cancer.
This historic partnership brings together two institutions dedicated to improving community health, combining Y-USA's 175-year legacy in communities across America with AstraZeneca's bold ambition to eliminate cancer as a cause of death.
Over the first two years, this partnership aims to reach 175,000 people across 75 communities nationwide by bringing tailored, community-driven solutions to increase awareness of cancer screening and early detection. In addition, Y-USA will strengthen its support for people navigating their cancer journey -- building on more than 15 years helping survivors reclaim their health and well-being while navigating their cancer journeys.
Mohit Manrao, Senior Vice President, Head of US Oncology, AstraZeneca and President, AstraZeneca Foundation, said: "We are in the golden era of cancer care, yet cancer screening and early detection rates for many types of cancer remain low, with significant disparities across zip codes. Our partnership with Y-USA can directly reach millions of Americans at scale and at the grassroots level because every patient, regardless of zip code, deserves support throughout their cancer journey."
Suzanne McCormick, President and CEO, Y-USA, said: "We are bringing together AstraZeneca's global expertise in life-changing innovations and the YMCA's expansive community reach to transform our nation's approach to cancer care. Over the next five years, we will expand screening, early detection, and survivorship programs to reach more people in the places they live and help them lead longer, healthier lives."
New data shows that people are living longer after a cancer diagnosis than ever before, reflecting significant advances in screening, early detection and more targeted treatments./1 At the same time, more people are being diagnosed with cancer,/2 underscoring the growing burden of the disease and the need for greater awareness, earlier intervention, and support across the full cancer journey.
According to a 2025 survey from Prevent Cancer Foundation, 51% of US adults 21 years of age and older say they have had a routine medical appointment or routine cancer screening in the last year, a 10% drop compared with its 2024 survey. However, 73% of those surveyed were more likely to schedule routine cancer screenings after learning about the benefits of early detection. 3 The five-year survival rate for many types of cancer is almost 90% when found early./2
* * *
Notes
AstraZeneca in Oncology
AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients.
The Company focuses on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyze changes in the practice of medicine and transform the patient experience.
AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.
* * *
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca-us.com and follow the Company on social media @AstraZeneca.
* * *
References
1. American Cancer Society. People Are Now Living Longer After a Cancer Diagnosis. Accessed June 10, 2026. https://www.cancer.org/research/acs-research-news/people-are-now-living-longer-after-a-cancer-diagnosis.html.
2. American Cancer Society. Cancer Facts & Figures 2025. Accessed June 10, 2026. https://preventcancer.org/education-outreach/2025-early-detection-survey/.
3. Prevent Cancer Foundation. 2025 Early Detection Survey. Accessed June 10, 2026. https://preventcancer.org/education-outreach/2025-early-detection-survey/.
* * *
Original text here: https://www.astrazeneca-us.com/content/az-us/media/press-releases/2026/AstraZeneca-and-YMCA-of-the-USA-Announce-Landmark-Partnership-Aimed-to-Address-Gaps-in-Cancer-Care.html
[Category: BizPharmaceuticals]
* * *
AstraZeneca and YMCA of the USA Announce Landmark Partnership Aimed to Address Gaps in Cancer Care
Five-year, multimillion-dollar partnership kicks off with cancer screening and early detection education initiative in 75 communities
-
AstraZeneca and YMCA of the USA (Y-USA) announced today at the Aspen Ideas: Health conference, a five-year partnership focused on strengthening cancer education in the areas of screening and early detection to evidence-based programs ... Show Full Article WILMINGTON, Delaware, June 25 -- AstraZeneca, a biopharmaceutical company, issued the following news release on June 24, 2026: * * * AstraZeneca and YMCA of the USA Announce Landmark Partnership Aimed to Address Gaps in Cancer Care Five-year, multimillion-dollar partnership kicks off with cancer screening and early detection education initiative in 75 communities - AstraZeneca and YMCA of the USA (Y-USA) announced today at the Aspen Ideas: Health conference, a five-year partnership focused on strengthening cancer education in the areas of screening and early detection to evidence-based programshelping cancer survivors living with, through and beyond cancer.
This historic partnership brings together two institutions dedicated to improving community health, combining Y-USA's 175-year legacy in communities across America with AstraZeneca's bold ambition to eliminate cancer as a cause of death.
Over the first two years, this partnership aims to reach 175,000 people across 75 communities nationwide by bringing tailored, community-driven solutions to increase awareness of cancer screening and early detection. In addition, Y-USA will strengthen its support for people navigating their cancer journey -- building on more than 15 years helping survivors reclaim their health and well-being while navigating their cancer journeys.
Mohit Manrao, Senior Vice President, Head of US Oncology, AstraZeneca and President, AstraZeneca Foundation, said: "We are in the golden era of cancer care, yet cancer screening and early detection rates for many types of cancer remain low, with significant disparities across zip codes. Our partnership with Y-USA can directly reach millions of Americans at scale and at the grassroots level because every patient, regardless of zip code, deserves support throughout their cancer journey."
Suzanne McCormick, President and CEO, Y-USA, said: "We are bringing together AstraZeneca's global expertise in life-changing innovations and the YMCA's expansive community reach to transform our nation's approach to cancer care. Over the next five years, we will expand screening, early detection, and survivorship programs to reach more people in the places they live and help them lead longer, healthier lives."
New data shows that people are living longer after a cancer diagnosis than ever before, reflecting significant advances in screening, early detection and more targeted treatments./1 At the same time, more people are being diagnosed with cancer,/2 underscoring the growing burden of the disease and the need for greater awareness, earlier intervention, and support across the full cancer journey.
According to a 2025 survey from Prevent Cancer Foundation, 51% of US adults 21 years of age and older say they have had a routine medical appointment or routine cancer screening in the last year, a 10% drop compared with its 2024 survey. However, 73% of those surveyed were more likely to schedule routine cancer screenings after learning about the benefits of early detection. 3 The five-year survival rate for many types of cancer is almost 90% when found early./2
* * *
Notes
AstraZeneca in Oncology
AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients.
The Company focuses on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyze changes in the practice of medicine and transform the patient experience.
AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.
* * *
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca-us.com and follow the Company on social media @AstraZeneca.
* * *
References
1. American Cancer Society. People Are Now Living Longer After a Cancer Diagnosis. Accessed June 10, 2026. https://www.cancer.org/research/acs-research-news/people-are-now-living-longer-after-a-cancer-diagnosis.html.
2. American Cancer Society. Cancer Facts & Figures 2025. Accessed June 10, 2026. https://preventcancer.org/education-outreach/2025-early-detection-survey/.
3. Prevent Cancer Foundation. 2025 Early Detection Survey. Accessed June 10, 2026. https://preventcancer.org/education-outreach/2025-early-detection-survey/.
* * *
Original text here: https://www.astrazeneca-us.com/content/az-us/media/press-releases/2026/AstraZeneca-and-YMCA-of-the-USA-Announce-Landmark-Partnership-Aimed-to-Address-Gaps-in-Cancer-Care.html
[Category: BizPharmaceuticals]